Enliven Therapeutics (ELVN) Competitors

Zai Lab (NASDAQ:ZLAB) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Which has more risk and volatility, ZLAB or ELVN?

Zai Lab has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Which has preferable valuation & earnings, ZLAB or ELVN?

Enliven Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$398.99M	8.60	-$334.62M	-$2.59	-12.03
Enliven Therapeutics	N/A	N/A	-$71.58M	-$1.89	-10.50

Is ZLAB or ELVN more profitable?

Enliven Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -76.14%. Enliven Therapeutics' return on equity of -29.46% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-76.14%	-36.97%	-27.10%
Enliven Therapeutics	N/A	-29.46%	-27.33%

Do analysts rate ZLAB or ELVN?

Zai Lab currently has a consensus target price of $47.37, suggesting a potential upside of 52.06%. Enliven Therapeutics has a consensus target price of $40.33, suggesting a potential upside of 103.19%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enliven Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the MarketBeat Community prefer ZLAB or ELVN?

Zai Lab received 220 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 64.53% of users gave Zai Lab an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 231 64.53%	Underperform Votes 127 35.47%
Enliven Therapeutics	Outperform Votes 11 100.00%	Underperform Votes No Votes

Does the media prefer ZLAB or ELVN?

In the previous week, Zai Lab had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 9 mentions for Zai Lab and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.33 beat Zai Lab's score of 0.89 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of ZLAB or ELVN?

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 13.9% of Zai Lab shares are held by insiders. Comparatively, 29.2% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Enliven Therapeutics beats Zai Lab on 12 of the 17 factors compared between the two stocks.